Drug-induced phospholipidosis: Issues and future directions

Expert Opinion on Drug Safety

Volumn 5, Issue 4, 2006, Pages 567-583

  Reasor, Mark J ^a   Hastings, Kenneth L ^b   Ulrich, Roger G ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c ROSETTA INPHARMATICS   (United States)

Author keywords

Drug induced injury; Lysosomal storage disorder; Phospholipase; Phospholipidosis

Indexed keywords

AMIODARONE; AMPHOPHILE; ANOREXIGENIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CATIONIC AMPHIPHILIC DRUG; CHLORCYCLIZINE; CHLOROQUINE; CHLORPHENTERMINE; FLUOXETINE; GENTAMICIN; IMIPRAMINE; LEUKOCYTE ELASTASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MUCOLYTIC AGENT; NEUROLEPTIC AGENT; PHOSPHOLIPID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRANQUILIZER; TROSPECTOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTATION; ANTIPHOSPHOLIPID SYNDROME; CELL FUNCTION; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG WITHDRAWAL; FLUORESCENCE ANALYSIS; HUMAN; LAMELLAR BODY; LIPID STORAGE; LIPIDOSIS; LIVER TOXICITY; LUNG FIBROSIS; LUNG TOXICITY; NEPHROTOXICITY; NIEMANN PICK DISEASE; NONHUMAN; PATHOGENESIS; PNEUMONIA; REVIEW; SCREENING TEST; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; TOXICOGENETICS; TRANSMISSION ELECTRON MICROSCOPY; VALIDATION STUDY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; HISTAMINE H1 ANTAGONISTS; HUMANS; LIPIDOSES; LIVER; LUNG; LYSOSOMES; MOLECULAR STRUCTURE; PHOSPHOLIPIDS; SEROTONIN UPTAKE INHIBITORS;

EID: 33749128073     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.4.567     Document Type: Review

References (126)

1. NELSON AA, FITZHUGH OG: Chloroquine: pathological changes observed in rats which for two years had been fed various proportions. Arch. Pathol. (1948) 45:454-462.
2. HRUBAN Z: Pulmonary changes induced by amphiphilic drugs. Environ. Health Perspect. (1976) 16:111-118.
3. ROBISON RL, VISSCHER GE, ROBERTS SA, ENGSTROM RG, HARTMAN HA, BALLARD FH: Generalized phospholipidosis induced by an amphiphilic cationic psychotropc drug. Toxicol. Path. (1985) 13:335-348.
4. LÜLMANN-RAUCH R: Drug-induced lysosomal storage disorders. In: Lysosomes in Biology and Pathology, Dingle JT, Jacques PJ, Shaw IH (Eds.), North-Holland, Amsterdam, The Netherlands (1979): 6:49-130.
5. REASOR MJ: Drug-induced lipidosis and the alveolar macrophage. Toxicology (1981) 20:1-33.
6. REASOR MJ: Phospholipidosis in the alveolar macrophage induced by cationic amphiphilic drugs. Federation Proc. (1984) 43:2578-2581.
7. REASOR MJ: Role of the alveolar macrophage in the induction of pulmonary phospholipidosis: pharmacologic and toxicologic considerations. In: Current Topics in Pulmonary Pharmacology and Toxicology, Hollinger MA (Ed), Elsevier Science Publishing Go, Inc., New York (1987):43-71.
8. REASOR MJ: A review of the biology and toxicological implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. (1989) 97:47-56.
9. REASOR MJ: Cationic amphiphilic drugs. In: Comprehensive Toxicology, Sipes IG, McQueen CA, Gandolfi AJ (Eds.), Toxicology of the Respiratory System, Roth RA (Ed.) Elsevier Science, Inc., New York, USA (1997) 8:555-566.
10. REASOR MJ, KACEW S: Drug-induced phospholipidosis: Are there functional consequences? Exp. Bio. Med. (2001) 226:825-830.
11. HOSTETLER KY: Molecular studies of the induction of cellular phospholipidosis by cationic amphiphilic drugs. Fed. Proc. (1984) 43:2582-2585.
12. LÜMANN H, LÜLMANN-RAUCH R, WASSERMANN O: Drug-induced phospholipidosis. Crit. Rev. Toxicol. (1975) 4:185-218.
13. HRUBAN Z: Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspec. (1984) 55:53-76.
14. KACEW S, REASOR MJ, RUBEN Z: Cationic lipophilic drugs: mechanisms of action, potential consequences, and reversibility. Drug Metab. Rev. (1997) 29:355-368.
15. HALLIWELL WH: Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. (1997) 25:53-60.
16. HOOK GE: Alveolar proteinosis and phospholipidosis of the lungs. Toxicol. Pathol. (1991) 19:482-513.
17. KODAVANTI UP, MEHENDALE HM: Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Res. (1990) 42:327-354.
18. XIA Z, YING G, HANSSON AL et al.: Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog. Neurobiol. (2000) 60:510-512.
19. DE LA IGLESIA FA, FEUER G, MCGUIRE EJ, TAKADA A: Morphological and biochemical changes in the liver of various species in experimental phospholipidosis after diethylaminoethoxyhexestrol treatment. Toxicol. Appl. Pharmacol. (1977) 34:28-44.
20. SEILER K-U, WASSERMANN O: Drug-induced phospholipidosis. II Alterations in the phospholipid pattern of organs from mice, rats and guinea pids after chronic treatment with chlorphentermine. Naunyn-Schmiedeberg's. Arch. Pharmacol. (1975) 288:261-268.
21. KACEW S: Alterations in newborn and adult rat lung morphology and phospholipid levels after chlorcyclizine or chlorphentermine treatment. Toxicol. Appl. Pharmacol. (1982) 65:100-108.
22. REASOR MJ, OGLE CL, KACEW S: Amiodarone-induced pulmonary toxicity in rats: Biochemical and pharmacological characteristics. Toxicol. Appl. Pharmacol. (1989) 97:124-133.
23. MARTIN WJ III, STANDING JE: Amiodarone pulmonary toxicity: Biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J. Pharmacol. Eur. Ther. (1988) 244:774-779.
24. TASHIRO Y, WATANABE Y, ENOMOTO Y: Experimental phospholipidosis induced by 4,4′-diethyl-aminoethoxyhexestrol. Morphological and biochemical interpretations. Acta Pathol. Jpn. (1983) 33:929-942.
25. OGLE CL, REASOR MJ: Response of alveolar macrophages to amiodarone and desethylamiodarone, in vitro. Toxicology (1990) 62:227-238.
26. WILSON BD, CLARKSON CE, LIPPMANN ML: Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite and phospholipid. Am. Rev. Resp. Dis. (1991) 143:1110-1114.
27. LÜLMANN-RAUCH R, NÄSBERGER L: Citalopram-induced generalized lipidosis in rats. Acta Pharmacol. Toxicol. (1983) 52:161-167.
28. LELI U, HAUSER G: Modifications of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. Biochem. Pharmacol. (1987) 36:31-37.
29. LÜLMANN-RAUCH R, REIL GH: Chlorphentermine-induced ultrastructural changes in liver tissues of four animal species. Virchows Arch. Abt. B Zellpath. (1973) 13:307-320.
30. KACEW S: Gentamicin or chlorphentermine induction of phospholipidosis in developing organism: Role of tissue and species in manifestation of toxicity. J. Pharmacol. Exp. Ther. (1984) 232:239-243.
31. THOMA-LAURIE DL, WALKER ER, REASOR MJ: Chlorphentermine-induced neonatal and maternal pulmonary phospholipidosis in rats. Exp. Molec. Pathol. (1983) 38:310-321.
32. LÜLMANN-RAUCH R: Chlorphentermine-induced lipidosis-like ultrastructural alterations in lungs and adrenal glands of several species. Toxicol. Appl. Pharmacol. (1974) 30:408-421
33. DARMANATA JI, VAN ZANDWIJK N, VAN ROYEN EA et al.: Amiodarone pneumoniits: three further cases with a review of published reports. Thorax (1984) 39:57-64.
34. REASOR MJ, OGLE CL, WALKER ER, KACEW S: Amiodarone induced phospholipidosis in rat alveolar macrophages. Am. Rev. Respir. Dis. (1988) 137:510-518.
35. GUM RJ, HICKMAN D, FAGERLAND JA et al.: Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. (2003) 62:1661-1673.
36. LÜLMANN H, LÜLMANN-RAUCH R, WASSERMANN O: Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. (1978) 27:1103-1108.
37. HOSTETLER KY, REASOR M, YAZAKI PJ: Chloroquine-induced phospholipid fatty liver: Measurement of drug and lipid concentrations in rat liver lysosomes. J. Biol. Chem. (1985) 260:215-219.
38. REASOR MJ, MCCLOUD CM, BEARD TL et al.: Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fisher-344 and Sprague-Dawley rats. Toxicology (1996) 106:139-147.
39. VAN BAMBEKE F, MONTENEZ JP, PIRET J, TULKENS PM, COURTOY JPJ, MINGEOT-LECLERCO MP: Interaction of the macrolide azithormycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity Eur. J. Pharmacol. (1996) 314:203-214.
40. APPELKVIST E-L, SÖERSTRÖ M, NÄSBERGER L, DAMBERG C, DALLNER C, DEPIERRE JU: Characterization of the lipid and protein contents of myelin bodies isolated from the renal cortex of gentamicin-treated rats. Biochem. Biophys. Res. Com. (1991) 181:894-901.
41. KUBO M, HOSTETLER, KY: Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry (1985) 24:6515-6520.
42. MA JYC, MA JKH, WEBER KC: Fluorescence studies of the binding of amphiphilic amines with phospholipids. J. Lipid Res. (1985) 26:735-744.
43. JOSHI UM, RAO P, DODAVANTI S, LOCKARD VG, MEHENDALE HM: Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochem. Biophys. Acta (1989) 1004:309-320.
44. PAPPU A, HOSTETLER KY: Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem. Pharmacol. (1984) 33:1639-1644.
45. ULRICH, RG, KILGORE KS, SUN EL, CRAMER CT, GINSBERG LC: An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol. Methods (1991) 1:89-105.
46. CRAMER CT AND ULRICH RG: Cytotoxicity and lamellar body induction potential of a racemic benzamide antiarrhythmic compound and enantiomers in cultured rat hepatocytes. Toxicol. in vitro (1994) 5:1083-1090.
47. SLEIGHT RG, PAGANO RE: Transport of a fluorescent phosphatidylcholine analog from the plasma membrane to the Golgi apparatus. J. Cell Biol. (1984) 99:742-751.
48. HAO M, MAXFIELD FR: Characterization of rapid membrane internalization and recycling. J. Biol. Chem. (2000) 275:15279-86.
49. MAXFIELD FR, MCGRAW TE: Endocytic recycling. Nat. Rev. Mol. Cell. Biol. (2004) 5:121-132.
50. ULRICH RG, PETRELLA DK, LARSEN ER et al.: Hepatic changes produced by 30-day administration of a novel aminocyclitol antibiotic, trospectomycin sulfate, to laboratory animals. Fundam. Appl. Toxicol. (1990) 14:60-70.
51. REASOR MJ, CASTBANOVA V: Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. I. Biochemical and cellular features. Exp. Molec. Pathol. (1981) 35:359-369.
52. REASOR MJ, WALKER ER: Recovery from chlorphentermine-induced phospholipidosis in rat alveolar macrophages. II. Morphological features. Exp. Molec. Pathol. (1981) 35:370-399.
53. MCCLOUD CM, BEARD TL, KACEW S, REASOR MJ: In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. Exp. Molec. Pathol. (1995) 62:12-21.
54. GUIGUI B, PERROT S, BERRY JP et al.: Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology (1988) 8:1063-1068.
55. CHEW E, GHOSH M, MCCULLOCH C: Amiodarone-induced cornea verricillata. Can. J. Ophthalmol. (1982) 17:96-99.
56. LIM PK, TREWBY PN, STOREY GCA, HOLT DW: Neuropathy and fatal hepatitis in a patient receiving amiodarone. Br. Med. J. (1984) 288:1638-1639.
57. SIMON JB, MANLEY PN, BRIEN JF, ARMSTRONG PW: Amiodarone hepatotoxicity simulating alcoholic liver disease. N. Engl. J. Med. (1984) 311:167-172.
58. ITOH S, TSUKADA Y: Clinico-pathological and electron microscopical studies on a coronary dilating agent: 4,4′-diethylaminoethoxyhexestrol-induced liver injuries. Acta Hepato-Gastroent. (1973) 20:204-215.
59. KANNAN R, NADEMANNE K, HENDRICKSON JA, ROSTAMI HJ, SINGH BN: Amiodarone kinetics after oral doses. Clin. Pharmacol. Ther. (1982) 32:438-444.
60. REASOR MJ, MCCLOUD CM, DIMATTEO M, SCHAFER R, IMA A, LEMAIRE I: Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Proc. Soc. Exptl. Biol. Med. (1996) 211:346-352.
61. MCNULTY MJ, REASOR MJ: Enhanced phagocytic and bactericidal activities of phospholipidotic rat alveolar macrophages. J. Reticuloendothel. Soc. (1981) 30:539-549.
62. WAITES CR, BUGLESKI PJ, BADGER AM: Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions. Toxicol. Appl. Pharmacol. (1995) 130:316-321.
63. FERIN J: Alveolar macrophage mediated pulmonary clearance suppressed by drug-induced phospholipidosis. Exp. Lung Res. (1982) 4:1-10.
64. SUN EL, PETRELLA DK, MCCLOUD CM, CRAMER CT, REASOR MJ, ULRICH RG: Amiodarone-induced cytoplasmic lamellar body formation in cultured primary rat and human hepatocytes: relationship to cell function and cytotoxicity. In vitro Toxicol. (1997) 10:459-470.
65. SAUERS LJ, WIERDA D, WALKER ER, REASOR MJ: Morphological and functional changes in mouse splenic lymphocytes following in vivo and in vitro exposure to chlorphentermine. J. Immunopharmacol. (1986) 8:611-631.
66. PICCOTTI JR, LAGATTULA MS, KNIGHT SA, GONZALES AJ, BLEAVINS MR: Induction of apoptosis by cationic amphiphilic drugs amiodarone and imipramine. Drug Chem. Toxicol. (2005) 1:117-133.
67. DRENCKHAHN D, LULLMANN-RAUCH R: Lens opacities associated with lipidosis-like ultrastructural alterations in rats treated with chloroquine, chlorphentermine, or iprindole. Exp. Eye Res. (1977) 24:621-632.
68. MANTYJARVI M, TUPPURAINEN K, IKAHEIMO K: Ocular side effects of amiodarone. Surv. Ophthalmol. (1998) 42:360-366.
69. HALLBERG A, NAESER P, ANDERSSON A: Effects of long-term chloroquine exposure on the phospholipid metabolism in retina and pigment epithelium of the mouse. Acta Ophthalmol. (Copenh). (1990) 68:125-130.
70. ANTONINI JM, MCCLOUD CM, REASOR MJ: Acute silica toxicity: Attenuation by amiodarone-induced pulmonary phospholipidosis. Environ. Health Perspect. (1994) 102:372-378.
71. BLAKE TL, DIMATTEO M, ANTONINI JM, MCCLOUD CM, REASOR MJ: Subchronic pulmonary inflammation and fibrosis induced by silica in rats are attenuated by amiodarone. Exp. Lung Res. (1996) 22:113-131.
72. HASTINGS CE, DENICOLA DB, REBAR AH, TUREK JJ, BORN GA, KESSLER MW: The effect of chlorphentermine pretreatment on the toxicity of nitrogen dioxide in mice. Fundam. Appl. Toxicol. (1987) 9:69-81.
73. KALOYANIDES GJ, PASTORIZA-MUNOZ E: Aminoglycoside nephrotoxicity. Kidney Int. (1980) 18:571-582.
74. LAURENT G, KISHORE BK, TULKENS PM: Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem. Pharmacol. (1990) 40:2383-2392.
75. KISHORE BK, IBRAHIM S, LAMBRICHT P et al.: Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats. J. Pharmacol. Exp. Ther. (1992) 262:424-432.
76. SAMADLAN T, DEHPOUR AR, SMINI S, NOUHNEJAD P: Inhibition of gentamicin-induced nephrotoxicity by lithium in the rat. Histol. Histopath. (1993) 8:139-147.
77. EL-MOUEDDEN M, LAURENT G, MINGEOT-LECLERQ MP et al.: Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob. Agents Chemother. (2000) 44:665-675.
78. ULRICH RG, COX JW: Acute hepatocellular changes elicited by various antibiotics in the perfused liver and cultured hepatocytes from the rat. In: Liver Cells and Drugs, Guillouzo A (Ed.), John Libbey Eurotext Ltd (1988):391-396.
79. ULRICH RG, CRAMER CT: Potential to induce lamellar bodies and acute cytotoxicity of 6′alkyl analogues of spectinomycin in primary cultures of rat hepatocytes. Toxicol. in vitro (1991) 5:239-245.
80. COX J, ULRICH RG, LARSON PG, CRAMER CT: Acute hepatocellular effects of erythromycin, gentamicin, and trospectomycin in the perfused rat liver: Lack of correlation between lamellar body induction potency and cytotoxicity. Pharmacol. Toxicol. (1988) 62:337-343.
81. GRAY JE, PURMALIS A, PURMALIS B, MATHEWS J: Ultrastructural studies of the hepatic changes brought about by Clindamycin and Erythromycin in animals. Toxicol. Appl. Pharmacol. (1971) 19:217-233.
82. HORN JW, JENSEN CB, WHITE SL et al.: In vitro and in vivo ultrastructural changes induced by macrolide antibiotic LY281389. Fundam. Appl. Toxicol. (1996) 32:205-216.
83. DAKE MD, MADISON JM, MONTGOMERY CK et al.: Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary phospholipidosis. Am. J. Med. (1985) 78:506-512.
84. LEWIS JH, MULLICK F, ISHAK KG et al.: Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum. Pathol. (1990) 21:59-67.
85. FROMENTY B, FISCH C, LABBE G et al.: Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. (1990) 255:1371-1376.
86. PESSAYRE D, BICHARA M, DEGOTT C, POTET F, BENHAMOU JP, FELDMANN G: Perhexiline maleate-induced cirrhosis. Gastroenterology (1979) 76:170-177.
87. STRAVITZ RT, SANYAL AJ: Drug-induced steatohepatitis. Clin. Liver Dis. (2003) 7:435-451.
88. DE BROE ME, PAULUS GJ, VERPOOTEN GA, ROELS F, BUYSSENS N, WEDEEN R et al.: Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int. (1984) 25:643-652
89. MINGEOT-LECLERCQ MP, TULKENS PM: Aminoglycosides: nephrotoxicity. Antimicrob. Agents Chemother. (1999) 43:1003-1012.
90. LÜLMANN-RAUCH R: Chlorphentermine-induced abnormal cytoplasmic inclusions in peripheral blood cells of rats and guinea pigs. Toxicol. Appl. Pharmacol. (1975) 32:32-39
91. RUDMANN DF, MCNERNEY ME, VANDEREIDE SL, SCHEMMER JK, EVERSOLE RR, VONDERFECHT SL: Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Toxicol. Pathol. (2004) 32:326-336.
92. HALSTEAD BW, ZWICKL CM, MORGAN RE et al.: A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile red. J. Appl. Toxicol. (2006) 26:169-177.
93. FEDORKO M: Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes - an ultrastructural study. J. Clin. Invest. (1967) 46:1932-1942.
94. HOSTETLER KY, VANDE BERG J, ALDERN KA, BROPHY GT: Effect of amiodarone on the phsopholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochem. Pharmacol. (1991) 41:1007-1013.
95. BROWN WJ, SULLIVAN TR, GREENSPAN P: Nile red staining of lysosomal phospholipid inclusions. Histochemistry (1992) 97:349-354.
96. DELANEY J, NEVILLE WA, SWAIN A, MILES A, LEONARD MS, WATERFIELD CJ: Phenylacetyl glycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipids accumulation using amiodarone treated rats as a model. Biomarkers (2004) 9:271-290.
97. ESPINA JR, SHOCKCOR JP, HERRON W et al.: Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magn. Reson. Chem. (2001) 39:559-565.
98. NICHOLLS AW, NICHOLSON JK, HASELDEN JN, WATERFIELD CJ: A metabonomic approach to the investigation of drug-induced phospholipidosis: an NMR spectroscopy and pattern recognition study. Biomarkers (2000) 5:410-423.
99. THOMAS CE, COLET JM, MEISSNER A et al.: Use of in vitro, technologies and metabonomics in the study of phospholipidosis. Toxicologist (2005) 84(S-1):106.
100. YAMAMOTO A, ADACHI S, KITANI T et al.: Drug-induced phospholipidosis in human cases and in animal experiments: Accumulation of an acidic gylcerophospholipid. J. Biochem. (Tokyo) (1971) 69:613-615.
101. YAMAMOTO A, ADACHI S, ISHIKAWA T et al.: Studies on drug-induced phospholipidosis III. Lipid composition of the liver and some other tissues in clinical cases of 'Nieman-Pick-like Syndrome' indiced by 4,4′-diethylaminoethoxyhexestrol. J. Biochem. (Tokyo) (1971) 70:775-784.
102. ADEKA S: A study on the lipidosis induced by a coronary vasodilator, 4,4′-diethylaminoethoxyhexestrol dihydrochloride. Mie Med. J. (1972-1973) 22:65-89.
103. HARDER A, KOVATCHEV S, DEBUCH H: Interactions of chloroquine with different glycerophospholipids. Hoppe Seylers Z. Physiol. Chem. (1980) 361:1847-1850.
104. MATSUZAWA Y, HOSTETLER KY: Studies on drug-induced lipidosis: subcellular localization of phopholipid and cholesterol in the liver of rats treated with chloroquine or 4,4′-bis(β-diethylaminoethoxy)α,β-diethyl diphenylethane. J. Lipid Res. (1980) 21:202-214.
105. MORTUZA GB, NEVILLE WA, DELENAY J, WATERFIELD CJ, CAMILLERI P: Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim. Biophys. Acta (2003) 1631:136-146.
106. ROBOSKY LC, ROBERTSON DG, BAKER JD, RANE S, REILY MD: In vivo toxicity screening programs using metabonomics. Comb. Chem. High Throughput Screen (2002) 5:651-662.
107. PETERS JU, HUNZIKER D, FISCHER H et al.: An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorg. Med. Chem. Lett. (2004) 14:3575-3578.
108. PLOEMEN JP, KELDER J, HAFMANS T et al.: Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. (2004) 55:347-355.
109. MORELLI JK, BUEHRLE M, POGNAN F, BARONE LR. FIELES W, CIACCIO PJ: Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. (2006) 22:15-27.
110. KASAHARA T, TOMITA K, MURANO H et al.: Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. (2006) 90:133-141.
111. CASARTELLI A, BONATO M, CRISTOFORI P et al.: A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. (2003) 19(3):161-176.
112. XIA Z, APPELKVIST E-L, DEPIERRE JW, NÄSBERGER L: Tricyclic antidepressant-induced lipidosis in human peripheral monocytes in vitro, as well as in a monocyte-derived cell line, as monitored by spectrofluorimetry and flow cytometry after staining with nile red. Biochem. Pharmacol. (1997) 53:1512-1532.
113. SAWADA H, TAKAMI K, ASAHI S: A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. (2005) 83:282-292.
114. AMIN RP, VICKERS AE, SISTARE F et al.: Identification of putative gene-based markers of renal toxicity. Environ. Health Perspec. (2004) 112:465-479.
115. FIELDEN MR, KOLAJA KL: The state-of-the-art in predictive toxicogenomics. Curr. Opin. Drug Discov. Devel. (2006) 9:84-91.
116. HAYES KR, BRADFIELD CA: Advances in toxicogenomics. Chem. Res. Toxicol. (2005) 18:403-14.
117. SEARFOSS GH, RYAN TP, JOLLY RA: The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol. Med. (2005) 5:53-64.
118. MCGOVERN MM, ARON A, BRODIE SE, DESNICK RJ, WASSERSTEIN MP: Natural history of Type A Niemann-Pick disease. Neurology (2006) 66:228-232.
119. HEPPLESTON AG, FLETCHER K, WYATT I: Abnormalities of lung lipids following inhalation of quartz. Experientia (1972) 28:938-939.
120. KRAMER JKG, SAUER FD, WOLYNETZ MS, FARNWORTH ER, JOHNSTON KM: Effects of dietary saturated fat on erucic acid induced myocardial lipidosis in rats. Lipids (1992) 27:619-623
121. MASSEY TE, LEEDER RG, RAFEIRO E, BRIEN JF: The 1994 Veylien Henderson Award of the Society of Toxicology of Canada. Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can. J. Physiol. Pharmacol. (1995) 73: 1675-1685.
122. OHMIYA Y, ANGEVINE LS, MEHENDALE HM: Effect of drug-induced phospholipidosis on pulmonary disposition of pneumophilic drugs. Drug Metab. Disp. (1983) 11:25-30.
123. CARLIER MB, GARCIA-LUQUE I, MONTENEZ J-P, TULKENS PM, PIRET J: Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int. J. Tissue React. (1994) 16:211-220.
124. YAN S, CHAI H, WANG H, YANG H, NAN B, YAO Q, CHEN C: Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery (2005) 138:464-473.
125. ERKAN D, LOCKSHIN MD: Antiphospholipid syndrome. Curr. Opin. Rheumatol. (2006) 18:242-248.
126. PICHLER WJ, SCHINDLER L, STAUBLI M, STADLER BM, DE WECK AL: Anti-amiodarone antibodies: detection and relationship to the development of side effects. Am. J. Med. (1988) 85:197-202.